El-Hibri Fuad Blog

Archive for the ‘Business’ Category

The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate the transfer of a broad spectrum of knowledge to the next generation of researchers.

Along with colleagues from industry, education, and government, Fuad El-Hibri is a member of the IBRA Board of Directors. The Alliance helps provide opportunities for students to build and develop important elements of scientific leadership, giving students the opportunity to grow into exceptional biomedical research leaders. IBRA firmly believes in the ability of outstanding researchers to transform today’s promise of cures and treatments into available therapies, drugs and prevention measures that enhance the world’s health.

Since its inception in 2000, the Scholars program has recruited gifted, inquiring, creative and dedicated minds for a uniquely designed doctoral program of training and investigative, exploration to challenges some of the worlds greatest minds to achieve IBRA’s main goal to create the premier PhD and MD/PhD program.

Advertisements

ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition provides Emergent with multiple, advanced stage candidates in the key disease areas of oncology and autoimmunity as well as access to novel and versatile protein therapeutic platforms. Trubion’s platforms have been designed to address the limitations of monoclonal antibodies and complement Emergent’s existing antibody therapeutic capabilities.

“Emergent’s acquisition of Trubion helps achieve our goal of diversifying beyond infectious diseases and marks an important step towards being a fully integrated biopharmaceutical company,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “We look forward to growing our presence in the state’s vibrant biotech community building on the strengths of the Emergent Seattle team in the field of biotherapeutics.”

Emergent will maintain research facilities in Seattle, Washington and the location will become a therapeutics-focused product development site.

ROCKVILLE, Md., Oct 13, 2010 — Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close.  Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for the third quarter and first nine months of 2010, recent business developments and the forecast for 2010. The conference call will be accessible by dialing 888/713-4211 or 617/213-4864 (international) and providing passcode 50859780. A webcast of the conference call will be accessible from the Company’s website at www.emergentbiosolutions.com, under “Investors”.

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PNP49E4W7.

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 97521313. The replay will be available through November 18. The webcast will be archived on the company’s website, www.emergentbiosolutions.com, under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., led by Chairman and CEO, Fuad El-Hibri, is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Fuad El-Hibri, CEO of Emergent BioSolutions Inc., announces that the company will be participating in the following investor conferences during June 2010:

  • The Jefferies & Company 2010 Global Life Sciences Conference
    New York, NY.
    June 8, 2010
    Corporate Overview Presentation
    11:00 AM Eastern
    There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.
  • The Needham & Company 9th Annual Healthcare Conference
    New York, NY.
    June 10, 2010
    Corporate Overview Presentation
    3:20 PM Eastern
    There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.

The Prince Alwaleed Bin Talaal Center for Muslim-Christian Understanding and The Royal Islamic Strategic Studies Centre published its first edition in what promises to be an annual series of insight into the movers and shakers of the Muslim world. Entitled The 500 Most Influential Muslims 2009, the book categorizes Muslims’ influential capacities into 15 categories: scholarly , political, administrative, lineage, preachers, women, youth, philanthropy, development, science and technology, arts and culture, Qu’ran reciters, media, radicals, international Islamic networks and issues of the day. As part of an ongoing series each week those receiving mention in North America will be highlighted. This week those who seem to have influence in Science and Technology will be highlighted. In this category, there are four people honored living in the United States.

Mohamad Chakaki is a founding member of Green Muslims, a Washington, D.C. group that seeks to relate sustainable environmental policy to faith. He works on projects in the US and the Middle East.

Fuad El Hibri is the CEO of Emergent BioSolutions, Inc. BioSolutions is a multinational bio-pharmaceutical company that is the sole-holder of the FDA-approved anthrax vaccine. He is also Chairman of the East West Resources Corporation and Chairman and Treasurer of the El Hibri Charitable Foundation.

Dr. Mehmet Oz is a cardiothoracic surgeon recently named one of the sexiest men alive for 2009. A frequent visitor of the Oprah Winfrey show and now host of his own show, he is a professor at Columbia University and leads numerous charities and organizations. He has authored several books on personal health.

Ahmed Zewail is the recipient of the 1999 Nobel Prize in Chemistry for his research on femotochemistry. He is the Linus Pauling Professor at the California Institute for Technology and was recently asked to serve at President Obama’s invitation as an adviser to the Presidential Council of Advisors on Science and Technology.

For more info: IBSN: 2009-9-4078

Source :
http://www.examiner.com/x-26018-SE-Michigan-Islamic-Examiner~y2009m12d27-500-Most-Influential-Muslims-Science-and-Technology?cid=edition-rss-Detroit

Daily Star

July 10, 2009

http://www.dailystar.com.lb/article.asp?edition_id=1&categ_id=3&article_id=104008

Chairman and CEO Fouad El Hibri insists that good business opportunities often arise in time of crisis, which he considers the best time for entrepreneurs to invest in new projects. “When the market is down, I believe that good opportunities arise and investors have better chances to find assets that are undervalued and able to provide wonderful returns in the future,” Hibri told The Daily Star.

“I see within any turmoil great opportunities,” he said.

Hibri, an American entrepreneur with Lebanese heritage, is the winner of Ernst & Young Entrepreneur of the Year 2009 Award in the Technology category in greater Washington. With great persistence and commitment, Hibri was able to successfully grow a pharmaceutical biotech facility that is worth hundreds of millions of dollars and was previously owned and run by the state of Michigan.

By Nihad Tobalian

Lebanese businessman Fuad El-Hibri is the “Entrepreneur of the Year for 2009” for the Washington, DC area, and earned this award from Ernst & Young’s Global Technology Group, which is given to honor businessmen who lead nascent companies to growth in their specialized area of work. He earned this award for leading his American company, “Emergent BioSolutions,” which he transformed from a stumbling company into a pioneer company in the field of development of medical vaccines. What are the details of this award, and the types of vaccines that the 51-year-old El-Hibri has developed?

During a meeting with Anwar, businessman Fuad El-Hibri, who spends his annual vacation in Lebanon, said:

From this award, “Ernst & Young” is seeking major companies that apply quality standards of work and production and the ability to develop new products, against the contribution of these companies in the development and preservation of the community. What helped us as “Emergent BioSolutions” to win this award, specifically for the category of technology in the Washington metropolitan area, is our adherence to the requirement of the award, especially after the recent acquisition of the company, which was for sale for approximately $25 million, and which has 170 employees. Through expansion and development strategy, the price of the company rose to between 400 and 500 million dollars, according to the New York Stock Exchange, as the price per share has risen from six dollars ten years ago to 26 dollars, in addition to increasing the number of employees to 600 employees, which helped us to increase the volume of our business, especially since our approved strategy was also based on a policy of expansion through the acquisition of three money losing companies in the United States, Britain and Germany.

Overseeing Companies

“Ernst & Young,” explains businessman Fuad El-Hibri, “is a global financial company that exercises financial control over companies, and honors those who achieve their aspirations and consequently, their achievements in the creative and innovative areas in the field of technology. After that, a panel of judges selects a ‘Leading Businessman.’ Ernst &Young selected me as the pioneer businessman for 2009 in the field of technology, in my capacity as owner of the company ‘Emergent BioSolutions.’ And while I am proud of the award, I am also proud of every employee in the company, because they all, in addition to being loyal to the company, believe in what we do, and devote themselves to work, especially since the scope of our work requires protecting human life. It is true that the company has a business face, but the primary nature of our work is to protect human life through the development of vaccines that will provide them with immunity against disease. The motto with which we operate the commercial side does not negate the human aspect.”

Oxford University

● You spoke about the specialized vaccines that the company you own develop. What are these vaccines? And against which diseases do they work?

– We are currently working on the development of several new vaccines, including a vaccine for tuberculosis. We, in this regard, are working to develop a special vaccine for this disease, and I can say we are in the advanced stages of testing which we have conducted in South Africa, as we are in the second stage, Phase b, results of which have been encouraging. After two years of testing this vaccine on a sample of children to determine its potency, we have reached the stage of measuring the potency and immunity of the vaccine. If the tests are successful tests, then we will move on to Phase III of the trials to expand the tests to include the category of adults who provide material support for the companies developing the typhoid vaccine. We also receive support from the “Wellcome Trust,” while our partner in these trials is the University of Oxford in the United Kingdom.

The second vaccine—according to El-Hibri—is related to hepatitis B, which would, if successfully tested, provide immunity for patients with this disease. It would also provide a treatment for the chronic diseases resulting from hepatitis B. Businessman Fuad El-Hibri explains, “Patients who suffer from this disease often experience hepatitis B turning into a chronic disease, which may lead, in advanced stages, to liver cancer or liver failure for good. The vaccine, which we are currently developing, helps the patient’s body to protect itself against the disease in terms of reducing and limiting the progress of the disease and limiting its spread in the body. If I were to be optimistic, I would say that this vaccine could eliminate the disease completely, but today, I would say that if we were able to alleviate the pressure of this disease on the patient’s body, then we would have achieved a great result in this area, namely the prevention of the deterioration of the patient’s health. With respect to this vaccine, we have reached the second phase of testing which was conducted on a sample of citizens in China.

A New Medical Development

● What about the work on a vaccine for cancer, for which effective medical treatments have not been found?

– We are working on a number of vaccines for multiple diseases, including for example, work on the development of a vaccine to increase the effectiveness of an old vaccine. For example, there is an effective vaccine for typhoid, but we are working to develop a single dose vaccine, to be administered orally, not with a needle. As for internal diseases, such as internal inflammations for example, we have two technical working groups at the company studying the possibility of trying to find volunteers to receive these vaccines. However, I think it is premature to talk about this vaccine, because we are still in the early stages of the work, and specifically, we are still at the exploration stage. However, in this connection, if we were to look at this issue from a scientific point of view, vaccines are the most advanced in the pharmaceutical industry. Biological studies have shown that vaccines, and immunity enhancement and vaccination are more mature in biological research than they are in the pharmaceutical industry.

● Those who are familiar with your curriculum vitae will find that you specialize in economics. What led you to work in the medical treatment field?
– By nature, I love to work on the development of medical treatments. True, I specialized in economics, where I got a diploma from Stanford University and then an advanced degree in business from Yale University, then worked as head of the Operations Department at Citibank Group and then in Hamilton, and both were of consulting nature that encompass different industries, from the financial industry to beverages to research management. After that, I moved to work for consulting firm Booz Allen Hamilton, but above all I love to work on the development of medical treatments, even though I do not have any scientific background in the field of medicine. However, the nature of my work in these institutions and companies helped me to get into this area. In addition, I was lucky to have a wonderful team that helped me and taught me, because the working group has a scientific background and its members are dreamers like me. They have taught me and helped me to penetrate this field.


Advertisements